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Abstract
Introduction: We investigated the effects on hemodynamics and gas exchange of a lipid emulsion
enriched with omega-3 fatty acids in patients with ARDS.
Methods: The design was a prospective, randomized, double-blind, parallel group study in our
Intensive Medicine Department of Vall d'Hebron University Hospital (Barcelona-Spain). We
studied 16 consecutive patients with ARDS and intolerance to enteral nutrition (14 men and 2
women; mean age: 58 ± 13 years; APACHE II score: 17.8 ± 2.3; Lung Injury Score: 3.1 ± 0.5; baseline
PaO2/FiO2 ratio: 149 ± 40). Patients were randomized into 2 groups: Group A (n = 8) received the
study emulsion Lipoplus® 20%, B.Braun Medical (50% MCT, 40% LCT, 10% ω-3); Group B (n = 8)
received the control emulsion Intralipid® Fresenius Kabi (100% LCT). Lipid emulsions were
administered during 12 h at a dose of 0.12 g/kg/h. Measurements of the main hemodynamic and gas
exchange parameters were made at baseline (immediately before administration of the lipid
emulsions), every hour during the lipid infusion, at the end of administration, and six hours after
the end of administration lipid infusion.
Results: No statistically significant changes were observed in the different hemodynamic values
analyzed. Likewise, the gas exchange parameters did not show statistically significant differences
during the study. No adverse effect attributable to the lipid emulsions was seen in the patients
analyzed.
Conclusion: The lipid emulsion enriched with omega-3 fatty acids was safe and well tolerated in
short-term administration to patients with ARDS. It did not cause any significant changes in
hemodynamic and gas exchange parameters.
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Introduction
The lipid emulsions generally used in the parenteral nutri-
tion of critically ill patients are rich in long-chain triglyc-
erides (LCT), especially linoleic acid (polyunsaturated
series 6 fatty acid; PUFA n-6, 18:2 n-6). These preparations
guarantee an optimal energy supply and prevent defi-
ciency in essential fatty acids[1]. These fatty acids, aside
from producing adverse metabolic effects (transitory
hyperlipidemias), can alter pulmonary gas exchange due
to their potentially proinflammatory properties [2].
The MCT/LCT emulsions are oxidized faster and provide
fewer amounts of PUFAs than a LCT emulsions. While
MCT emulsions do not interfere with eicosanoids synthe-
sis, it has been considered as neutral. Thus MCT/LCT
emulsions have been associated with a lower risk of lipid
peroxidation and fewer alterations of membrane struc-
tures[3].
Polyunsaturated fatty acids of the n-3 series (PUFA n-3)
are precursors of biologically active substances, e.g. the
series 3 and 5 eicosanoids. These molecules use the same
metabolic routes and compete for the same elongases and
desaturases as linoleic and arachidonic, but ultimately
they are mediators that have a much less active biological
profile than linoleic acid derivatives[4]. In 146 patients
with ARDS treated with an enteral diet rich in eicosapen-
taenoic acid, γ-linolenic, and antioxidants, an improved
PaO2/FiO2 ratio, and a reduction in pulmonary inflam-
matory response, frequency of new organ failures, days of
mechanical ventilation and long of stay in intensive care
were observed[5]. In 100 patients with acute pulmonary
injury receiving a similar enteral diet, oxygenation was
better, pulmonary compliance improved, and there was
less need for mechanical ventilation[6]. The administra-
tion of LCT emulsions has been associated with changes
in pulmonary function that depend on pulmonary dis-
ease, dose, duration, and speed of administration, and
kind of infused lipids [7,8].
Many patients with ARDS require sedoanalgesia and
myorelaxation, inducing intestinal ileus and making
intolerance to enteral nutrition. We hypothesized that
adding n-3 to a MCT/LCT emulsion used in parenteral
nutrition, should be beneficial because of the reduced
amount of PUFA, would be less toxic than a lipid emul-
sion based on soybean oil, and that the addition of fish oil
would be protective because of its anti-inflammatory
properties[4]. The present study evaluated the hemody-
namic changes and variations in pulmonary gas exchange
that occurred in patients with ARDS given an intravenous
lipid emulsion enriched with n-3 fatty acids.
Materials and methods
Patients
We studied 16 consecutive patients with ARDS in the first
48 hours of admission and intolerance of enteral nutri-
tion defined by gastric aspirates higher than 300 ml.
Patients were enrolled after approval of the study by the
Committee of Clinical Trials of the Vall d'Hebron General
University Hospital of Barcelona. All the patients or their
representatives signed an informed consent before enroll-
ment in the study. The inclusion criteria were: bilateral
pulmonary infiltrates of sudden onset in the chest radio-
graph, PaO2/FiO2 less than 200, and pulmonary capillary
pressure less than 18 mm Hg[9]. Table 1 shows the clini-
cal characteristics of the patients studied. Patients were
excluded for age younger than 18 or older than 85 years,
pregnancy, liver failure, HIV positivity, leukopenia (<
3500 mm3), thrombocytopenia (< 100,000 mm3), severe
renal insufficiency (creatinine > 6 mg/dl) or need for renal
dialysis, signs of heart failure, transplantation, multiple
blood transfusions, participation in other clinical trials
simultaneously or in the last 60 days, treatment with
nitrous oxide or corticoids (prednisolone 2 mg/kg/d or
equivalent), multiple organ failure, severe dyslipidemia,
or propofol treatment.
Patients were sedated with morphine and midazolam and
muscular relaxation was used as needed. All patients were
ventilated mechanically (Mallinckrodt Puritan Bennett
7200 series, Carlsbad, CA, USA). Monitorization included
continuous electrocardiography (ECG), heart rate (HR),
pulse oximetry (SpO2), invasive blood pressure, pulmo-
nary artery catheterization, and continuous cardiac output
by thermodilution.
Measurements
A central venous catheter was inserted to administer the
lipid emulsions. The basic parameters of pulmonary
mechanics were monitored with the respirator and exter-
nal monitoring. Cardiac output (CO) was measured by
thermodilution. Systemic blood pressure (SBP), central
venous pressure (CVP), pulmonary artery pressure (PAP),
and pulmonary capillary pressure (PCP) were monitored
by transducers placed on the middle anteroposterior
chest, zeroed to atmospheric pressure, and calibrated elec-
tronically. Systemic (SVR) and pulmonary (PVR) vascular
resistance, O2  transport (DO2), and pulmonary Qs/Qt
were calculated with the usual formulas. Blood samples
were drawn under anaerobic conditions through catheters
placed in the radial artery and pulmonary artery. Oxygen
(PaO2) and carbon dioxide (PaCO2) partial pressure, pH,
and the concentration and mixed arterial and venous sat-
uration of haemoglobin were measured using standard
electrodes.Lipids in Health and Disease 2008, 7:39 http://www.lipidworld.com/content/7/1/39
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Study design
In the first 48 hours after the diagnosis of ARDS and
before receiving artificial nutrition, patients were rand-
omized into two different groups: Group A (n = 8)
received the study emulsion Lipoplus® 20%, B.Braun Med-
ical (50% MCT, 40% LCT, 10% ω-3); Group B (n = 8)
received the control emulsion Intralipid® 20% Fresenius
Kabi (100% LCT). The lipid emulsions were administered
during 12 hours at a rate of 0.12 g/kg/h. During the lipid
perfusion no recruitment maneuvres were done.
Measurements were made at baseline (immediately
before the administration of lipid emulsions, every hour
during the lipid infusion, at the end of lipid perfusion and
six hours latter. Data reported in tables: baseline (t 0), six
hours of perfusion (t 6); end of perfusion (t 12), and six
hours after perfusion (t 18). Basic parameters of pulmo-
Table 1: Clinical characteristics of patients
Diagnosis Sex Age PaO2/FiO2 LIS APACHEII PEEP Outcome
Group A: n-3
1. Pneumonia M 74 98 4 18 7 D
2. Pneumonia M 48 166 2.3 17 8 D
3. Pneumonia M 64 133 3.6 18 12 D
4. Sepsis M 50 189 3 15 10 L
5. Smoke aspiration M 40 132 3 16 11 L
6. Bronchoaspiration M 72 84 2.6 21 8 D
7. Mediastinitis M 70 147 3.3 19 10 L
8. Bronchoaspiration M 36 183 2.5 15 7 L
Total Group A: 8 M 56 ± 15 141 ± 37 3 ± 0.5 17.4 ± 2.1 9.1 ± 1.9 4D/4L
Group B: LCT
1. Pancreatitis F 52 152 3 16 11 L
2. Bronchoaspiration M 57 198 4 21 15 L
3. Bronchoaspiration M 56 177 2.6 17 9 D
4. Status postpneumectomy M 63 60 4 19 10 L
5. Pneumonia M 71 181 3 18 10 L
6. Pneumonia M 43 186 3.3 14 8 L
7. Pneumonia M 53 153 3 19 10 D
8. Pneumonia F 81 157 3 22 9 L
Total Group B 6M/2F 59 ± 12 158 ± 43 3.2 ± 0.5 18.2 ± 2.6 10.3 ± 2.1 2D/6L
Total n:16 14M/2F 58 ± 13 149 ± 40 3.1 ± 0.5 17.8 ± 2.3 9.7 ± 2 6D/10L
LIS: Lung Injury Score. APACHEII: Acute Physiology and Chronic Health Evaluation. PEEP: Positive End Expiratory Pressure. M: male. F: female. D: 
dead. L: alive.Lipids in Health and Disease 2008, 7:39 http://www.lipidworld.com/content/7/1/39
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nary mechanics, arterial and mixed venous gas analysis,
hemodynamic parameters, and oxygen transport were
measured at all stages.
Statistical analysis
The data were imported from Access databases to SPSS.
The following statistical parameters were calculated for
numerical variables: mean and standard desviation. Dif-
ferences in the means were analyzed by the T-test. Differ-
ences in time of the different parameters studied,
depending on the type of emulsion, were assessed by
repeated-measure analysis of variance (ANOVA). The
level of statistical significance was defined as p < 0.05.
Results
Characteristics of the study population
At baseline, the groups were comparable (table 1, 2 and
3). Probably because of the exclusion criteria, the majority
of the patients studied are patients with primary pulmo-
nary disease as primary etiology of the ARDS. Although
mortality was 50% in group A and 25% in group B, no sig-
nificant differences in survival between the two groups
were found. Probably the differences in mortality between
groups are a simple size question. The global mortality
rate in the ICU during the study period time was 22%; in
this ICU no patients with coronary disease or cardiovascu-
lar surgery were admitted. All patients were sedated with
midazolam and morphine in continuous perfusion and
underwent controlled-volume ventilation. No significant
modifications in the ventilation parameters were neces-
sary during the study period time. There were no signifi-
cant changes between the two groups.
Effect on gas exchange
After the administration of lipid emulsions, no significant
modifications, intragroup or intergroup, in gas exchange
or respiratory variables were observed (table 3)
Effect on hemodynamics
No significant differences were observed in either blood
pressure or any other parameter studied during the
administration of the lipid emulsions. Comparison of the
changes between the two groups only yielded significant
findings for pulmonary capillary pressure, which was
lower at the end of emulsion infusion in group A, which
received the lipid emulsion enriched with n-3 fatty acids.
The fluid balance and medications used were similar in
both groups (table 2).
Discussion
The results of the present study suggest that none of the
lipid emulsions administered at the rate and for the dura-
tion studied here produced gas exchange or hemody-
namic disturbances in patients with ARDS. This suggests
that the emulsions were clinically safe under these condi-
tions. The changes in gas exchange induced by lipid emul-
sions in patients with ARDS depend on various factors
such as the rate of administration and duration, composi-
tion of the lipid emulsions (as precursors of prostanoid
synthesis), and the characteristics of the study popula-
tions (tables 4a, and 4b).
Analysis of the cardiopulmonary effects of lipid emul-
sions in our previous studies and the literature yields con-
tradictory findings. In relation to the administration of
LCT enriched emulsions; in healthy adults the administra-
tion of 4 hours infusion of Intralipid was followed by a
significant increase in systolic and diastolic blood pres-
sure as well as heart rate[10]. 500 ml of LCT 20% infusion
increases pulmonary artery pressure and venous admix-
ture in critically ill patients. The changes observed were
temporary and coincidental with serum lipemia[11]. The
same authors, in ARDS patients observed that an infusion
of 20% LCT at 3.0 ± 0.3 mg/kg/min was followed by a
transitory reduction in PaO2/FIO2, and an increase in
MPAP, pulmonary vascular resistance and pulmonary
venous admixture[12]. In different type of patients, the
administration of 500 ml of LCT 10% in 4 h resulted in a
reduction of the PaO2/FiO2 ratio and increased P(A-a)O2
and intrapulmonary shunting only in patients with
ARDS[8]. Slow infusion of an LCT 20% emulsion (500 ml
in 10 h) to patients with pulmonary injury increased
intrapulmonary shunting, possibly by increasing the pro-
duction of endogenous vasodilators, while rapid adminis-
tration of the emulsion (500 ml in 5 h) increased MPAP
possibly due to synthesis of endogenous vasoconstric-
tors[7].
Athough, theorically, the administration of emulsions
enriched with MCT/LCT should have a neutral effect due
to the few amount of PUFAs, the review of the literature
was not concordant. In septic patients MCT/LCT adminis-
tration did not induce any alterations in pulmonary
hemodynamics, gas exchange, or distribution of ventila-
tion/perfusion[13]. No hemodynamic neither respiratory
modifications were observed in patients immediately
after valvular surgery[14] or in critically ill patients with
mechanical ventilation[15]. In contrast, deterioration of
oxygenation, compliance, and pulmonary vascular resist-
ance was observed after administering MCT/LCT to
patients with ARDS[16]. Our group analyzed the gas
exchange and pulmonary haemodynamic responses to
LCT or MCT/LCT in ARDS patients. LCT infusion was fol-
lowed by an increment in oxygen consumption without
alterations in arterial oxygenation probably by the benef-
ficial effect of the increase in cardiac output observed[17].
Also in patients with ARDS, while LCT infusion was fol-
lowed by an increase in MPAP, and in pulmonary venous
admixture, and a decrease in arterial PaO2, MCT/LCT infu-
sion produced an increase in oxygen consumption, car-Lipids in Health and Disease 2008, 7:39 http://www.lipidworld.com/content/7/1/39
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Table 2: Hemodynamic parameters
T-0 h (baseline, preinfusion) T-6 h T-12 h (final infusion) T-18 h (6 h postinfusion)
HR
A: n-3 91 ± 19 101 ± 20 100 ± 21 91 ± 25
B: LCT 95 ± 13 93 ± 12 95 ± 12 84 ± 16
CO
A: n-3 7.8 ± 2.8 8.4 ± 2.7 8.5 ± 2.7 7.8 ± 3
B: LCT 6.9 ± 1.3 7.3 ± 1.9 6.8 ± 1.6 6.1 ± 1.3
SAP
A: n-3 127 ± 19 113 ± 14 117 ± 15 131 ± 24
B: LCT 126 ± 9 126 ± 10 124 ± 14 121 ± 14
MPAP
A: n-3 26 ± 5 29 ± 4 28 ± 7 28 ± 6
B: LCT 30 ± 7 31 ± 7 31 ± 6 28 ± 7
PW
A: n-3 13 ± 4* 13 ± 2 14 ± 3 14 ± 4
B: LCT 16 ± 2 17 ± 2 17 ± 2 16 ± 2
PVR
A: n-3 162 ± 122 187 ± 98 155 ± 68 162 ± 92
B: LCT 147 ± 84 142 ± 102 138 ± 79 134 ± 77
SVR
A: n-3 822 ± 328 644 ± 194 629 ± 228 864 ± 376
B: LCT 863 ± 217 840 ± 274 884 ± 298 932 ± 238
DO2
A: n-3 1074 ± 340 1171 ± 406 1174 ± 372 1066 ± 518
B: LCT 966 ± 224 1023 ± 330 936 ± 227 856 ± 225
VO2/DO2
A: n-3 0.22 ± 0.04 0.24 ± 0.05 0.23 ± 0.04 0.25 ± 0.06
B: LCT 0.26 ± 0.05 0.25 ± 0.04 0.27 ± 0.03 0.25 ± 0.04
Qs/QtLipids in Health and Disease 2008, 7:39 http://www.lipidworld.com/content/7/1/39
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A: n-3 33 ± 10 31 ± 8 33 ± 11 28 ± 7
B: LCT 28 ± 11 27 ± 6 25 ± 8 25 ± 9
BT
A: n-3 38.1 ± 1 38 ± 0.9 38.1 ± 0.8 37.6 ± 1.2
B: LCT 37.6 ± 0.4 37.5 ± 0.6 37.6 ± 0.4 37.1 ± 1
HR: heart rate, CO: cardiac output, SAP: systolic artery pressure, MPAP: mean pulmonary artery pressure, PW: pulmonary artery occlusion 
pressure, PVR: pulmonary vascular resistances, SVR: systemic vascular resistances DO2: oxygen delivery, Qs/Qt: venous admixture ratio, BT: body 
temperature.
* p < 0.05 between baseline groups
Table 2: Hemodynamic parameters (Continued)
Table 3: Respiratory parameters
T-0 h (baseline, preinfusion) T-6 h T-12 h (final infusion) T-18 (6 h postinfusion)
PaO2/FiO2
A: n-3 137 ± 35 143 ± 44 161 ± 87 162 ± 59
B: LCT 158 ± 43 158 ± 47 184 ± 84 192 ± 66
pH
A: n-3 7.42 ± 0.07 7.41 ± 0.07 7.38 ± 0.06 7.41 ± 0.07
B: LCT 7.40 ± 0.07 7.41 ± 0.06 7.40 ± 0.06 7.41 ± 0.1
PaO2
A: n-3 90 ± 25 99 ± 17 127 ± 85 106 ± 30
B: LCT 101 ± 32 99 ± 31 113 ± 59 122 ± 42
PaCO2
A: n-3 42 ± 2.3 41.2 ± 4.9 44.6 ± 4.7 43.8 ± 5
B: LCT 40.5 ± 7.6 41.9 ± 8 41.3 ± 5 40.5 ± 6
ST BIC
A: n-3 26.6 ± 4.5 25.5 ± 4.7 25.6 ± 4.1 26.6 ± 3.4
B: LCT 24.5 ± 4 25.9 ± 5.4 25 ± 3.1 25.5 ± 5.2
BE
A: n-3 2.4 ± 4.6 0.9 ± 4.8 0.6 ± 4.5 1.9 ± 4.4
B: LCT 0.1 ± 4.4 1.2 ± 5 0.3 ± 4 0.9 ± 5.5
BE: base excess, ST BIC: standard bicarbonate.Lipids in Health and Disease 2008, 7:39 http://www.lipidworld.com/content/7/1/39
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diac output and CO2  production[18]. In critically ill
patients with mechanical ventilation, the infusion of
MCT/LCT vs LCT was accompanied by increased oxygen
consumption and minute ventilation[19]. A benefit in
oxygenation and increased cardiac output was demon-
strated in patients with ARDS treated with MCT/LCT lipid
emulsions compared to LCT[20]. From the revision of dif-
ferent data available using LCT, MCT/LCT fat emulsions
we observed contradictory effects on pulmonary and
hemodynamic variables; probably due to the different
pathologic situations, and the amount and rate of lipid
emulsions administered.
It seems that soy bean lipid emulsions represent an imbal-
anced fatty acid supply, with an overabundance of n-6
PUFAs. Emulsions that include MCT and fish oil as a par-
tial replacement for soy bean are now available, and evi-
dence to data is that these emulsions offer some
advantages over the use of soy bean alone. At the neutral
metabolic effects of MCTs they added the beneficial prop-
erties of n-3 fatty acids, with diminished circulating con-
centrations of inflammatory eicosanoids [21-23]. Several
studies in surgical and septic patients promotes the use of
omega-3 lipids in these clinical situations, however few
data from randomized controlled trials are available
[24,25]. In patients with ARDS, our group showed that
intravenous administration of an n-3 enriched lipid emul-
Table 4: Cardiopulmonary effects of LCT and MCT/LCT in humans
A (LCT)
Author Emulsion Infusion rate Patients Results
Venus[11] 20% LCT 100 g/10 h Sepsis
Non-sepsis
↑ MPAP, ↑ Qs/Qt
Venus[12] 20% LCT 100 g/8 h ARDS ↓ PaO2/FiO2
↑ MPAP, ↑ Qs/Qt, ↑ PVR
Hwang[8] 10% LCT 50 g/4 h Healthy
ARDS
Pneumonia
COPD
↓ Qs/Qt, ↑ PaO2/FiO2
↑ Qs/Qt, ↓ PaO2/FiO2
No changes
No changes
Mathru[7] 20% LCT 100 g/10 h
100 g/5 h
ARDS
ARDS
↑ Qs/Qt, =MPAP
=Qs/Qt, ↑ MPAP
B (MCT/LCT)
Radermacher[13] 20% MCT/LCT 50 g/4 h Sepsis No changes
Fiaccadori[14] 20% MCT/LCT 3.3 mg/kg min Heart surgery No changes
Masclans[17] 20% LCT
20% MCT/LCT
2 mg/kg/min 12 h
2 mg/kg/min 12 h
ARDS
ARDS
↑ CO
No changes
Smyrniotis[18] 20% LCT
20% MCT/LCT
50% non-prot cal Pancreatitis with ARDS ↑ MPAP, ↑ Qs/Qt, and ↓ PaO2/FiO2
↑ VO2, ↑ CO
Chassard[19] 20% LCT
20% MCT/LCT
3 mg/kg/min 8 h
3 mg/Kg/min 8 h
Sepsis No changes
↑ VO2
Faucher[20] 20% LCT
20% MCT/LCT
1 ml/kg/h 6 h
1 ml/kg/h 6 h
ARDS ↑ PaO2/FiO2, ↑ DO2
Lekka[16] 20% MCT/LCT
Placebo
ARDS: lipids
Placebo
↓ PaO2/FiO2, ↓ Comp, ↓ PVR
VO2: oxygen consumption, Comp: compliance.Lipids in Health and Disease 2008, 7:39 http://www.lipidworld.com/content/7/1/39
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sion was accompanied by the synthesis of a smaller
amount of proinflammatory mediators compared to LCT
100% emulsion[26].
Conclusion
In our series of patients with ARDS, no significant changes
were observed in hemodynamics or gas exchange, which
demonstrated the safety of n-3 enriched lipid emulsions
in these critical patients. The absence of theorically
expected changes related to modifications observed in the
eicosanoid profile may be due to the short duration of
treatment with lipid infusion. However, now that it has
been demonstrated that the n-3 enriched emulsion is safe,
it can be used for studies in patients with ARDS who
require PN. More prolonged use may reveal improve-
ments in the clinical evolution of this group of patients,
who traditionally bear a heavy morbidity and mortality.
Key messages
￿ Lipid n-3 enriched emulsions are safe in short term treat-
ments with ARDS patients.
￿ Despite theorical benefits in eicosanoid profile, the
absence of clinical benefit could be due to the short treat-
ment duration. Further studies are needed with longer
infusion treatments.
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